VLE Therapeutics
Paul McCabe is the Chief Operating Officer at VLE Therapeutics since February 2021. Prior to his current role, he served as Chair of BioPharmaChem Ireland (BPCI) since March 2020. Additionally, Paul is the Managing Director of Engage 4 Excellence Ltd since December 2020. He has held various leadership positions in companies such as Alexion Pharmaceuticals, Endo International plc, Amgen, Pfizer, Wyeth Biopharma, Intel Corporation, and Bristol Myers Squibb. Paul holds a B.Sc in Chemistry & Pharmacology from University College Dublin and various certifications in project management, Six Sigma, and human performance.
VLE Therapeutics
Vaccines, CGTs, and other advanced therapeutics are taking too long to reach patients. Scientists want to move faster, but external manufacturers prioritize ‘contracts’ over the need for innovation and speed in GMP manufacturing. The promise of patient-focused partnerships remains out of reach until now. *Speed through Science* VLE is led by the brightest scientific minds and powered by iACHIEVE© and BioACHIEVE© our digital and process science platforms. For every medicine, we redefine CMC, tech transfer, and GMP operations through digitization and scientific excellence creating a new frontier for medicine acceleration and a new state-of-the-art for GMP manufacturing. *Patient-Focused Partnerships* We constantly strive to understand the unique clinical and CMC landscape of every medicine we work on, enabling us to deliver the manufacturing breakthroughs our partners need to achieve audacious supply chain goals that truly serve patients. *Digital First GMP* Our expertise in manufacturing science and GMP operations is accentuated by our first-in-class digital strategy – iACHIEVE©. By digitizing our process, analytical and manufacturing science breakthroughs we can deliver medicines with the speed that patients deserve and the precision regulators demand.